Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial

Risk of hospitalization with sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes lacking evidence of chronic kidney disease: Real‐world data

“…5 Post hoc data of the DECLARE-TIMI 58 found a similar 11% reduction in risk of first hospitalizations in 17 160 patients with T2D, with creatinine clearance >60 mL/min, most of them (59.4%) with high risk for but without evidence of cardiovascular disease. 11 In the SOLOIST-WHF study involving patients with T2D and recent worsening HF, sotagliflozin increased the number of days alive and out of hospital. 10 Analyses from the EMPA-KID-NEY 9 and DAPA-CKD 8 trials found a lower risk of hospitalizations from any cause with empagliflozin and dapagliflozin, respectively, in patients with CKD with and without T2D.…”

“…These findings are in line with cumulating data from RCTs. [4][5][6][7][8][9][10] In the EMPA-REG OUTCOME trial, treatment with empagliflozin compared with placebo resulted in a significant 11% (95% CI [4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19] reduction in the risk of first hospitalization in patients with T2D and previous cardiovascular disease. 4 In the CANVAS program, which also included patients with high risk but without established cardiovascular disease, the risk of first all-cause hospitalization was one of the prespecified outcomes.…”

“…The risk of hospitalization may fluctuate at different seasons and due to pandemics. Finally, although SGLT2 inhibitors in RCTs had varying effects on different causes of hospitalizations, 8,9,11 we did not assess the risk of specific hospitalization aetiologies, limiting discussion on potential mechanisms. Future studies are needed to evaluate the effect of SGLT2 inhibitors on cause‐specific hospitalizations in real‐world settings.…”

“…Randomized controlled trials (RCTs) showed that sodium‐glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of cardiovascular events, heart failure (HF) hospitalizations, and kidney outcomes in patients with T2D, HF, or chronic kidney disease (CKD) 3 . In some of these RCTs, SGLT2 inhibitors also modestly reduced the risk for any hospitalization 4–11 . However, these studies included patients with T2D and high cardiovascular risk, 4–6,11 or patients with CKD with and without T2D 8,9 .…”

“…3 In some of these RCTs, SGLT2 inhibitors also modestly reduced the risk for any hospitalization. [4][5][6][7][8][9][10][11] However, these studies included patients with T2D and high cardiovascular risk, [4][5][6]11 or patients with CKD with and without T2D. 8,9 Whether SGLT2 inhibitor use is associated with a lower risk for any hospitalization in a general population of patients with T2D, especially patients without CKD, is unknown.…”